Liquidia's chief commercial officer sells shares worth $98,504

Published 14/01/2025, 22:44
Liquidia's chief commercial officer sells shares worth $98,504

Scott Moomaw, the Chief Commercial Officer of Liquidia Corp (NASDAQ:LQDA), has recently sold shares of the company valued at $98,504. The transaction, which took place on January 14, involved the sale of 8,362 shares at a price of $11.78 per share. The sale price was slightly above InvestingPro's Fair Value estimate, with analysts setting price targets ranging from $17 to $31.

This sale was conducted under a pre-established Rule 10b5-1 trading plan, which Moomaw adopted on December 15, 2023. According to the filing, the shares were sold to cover taxes associated with the settlement of restricted stock units (RSUs) that were initially granted in January 2023 and January 2024. The company, currently valued at nearly $967 million, maintains strong liquidity with a healthy current ratio of 6.33x.

Following this transaction, Moomaw holds 215,494 shares of Liquidia's common stock. This includes various unvested RSUs and shares acquired under the company's 2020 Employee Stock Purchase Plan. InvestingPro subscribers can access 10+ additional exclusive insights about LQDA's financial health, valuation metrics, and growth prospects through the comprehensive Pro Research Report.

In other recent news, Liquidia Corporation reported a rise in its Q3 revenue, reaching $4.4 million, an increase from the previous year's $3.7 million. However, the company also reported a net loss of $23.2 million. Despite this, Liquidia maintains a robust cash position, with $204.4 million in reserves. The company is making strides towards the launch of its inhaled treatment, YUTREPIA, for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The launch is anticipated post the expiration of TYVASO DPI's exclusivity in May 2025. Liquidia is also progressing with the development of a next-generation nebulizer and preparing for a pivotal study of their product L606. These recent developments underline Liquidia's commitment to innovation and patient care.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.